Our website will soon be relaunched with a fresh look and improved user experience. Take a look by visiting our test site.
Call us 24/7 at (888) 552-6760
Cancer Treatment Centers of America

Our cancer treatment statistics and results

When you are exploring cancer treatment options, you may want to know about issues like life expectancy and quality of life. To help you and your family make more informed decisions about your cancer treatment, we publish our patient survival rates along with patient experience, quality of life and patient safety program results.

Currently, Cancer Treatment Centers of America® (CTCA) treatment results are available for the 11 most prevalent cancers we treat, with lung cancer broken down into two separate types: non-small cell lung cancer and small cell lung cancer.



Patient Treatment Results 2017/2018 Book
Downloadable PDF Version

Our quality of life results

Assessment background & methodology

Cancer Treatment Centers of America® (CTCA), was among the first U.S. cancer hospitals to use quality of life metrics as part of its routine assessment of patient well-being and quality of care. Research demonstrates Patient Self-Reported Outcome (PRSO) data are a valuable part of a patient’s treatment plan. Several studies validate the potential of routine assessment data in improving both the precision and degree of patient-centered care – making sure the right care is delivered to the right patients at the right time. The benefits of PSRO data not only include better health-related quality of life and fewer emergency room visits, but also improvements in health service outcomes and survival.1,2,3

CTCA® patients self-report their symptoms and quality of life concerns as part of our patient evaluation process. This process includes a symptom assessment, called the Symptom Inventory Tool (SIT), that patients complete in correspondence with their treatment cycle, not more frequently than every 21 days. Upon arrival, patients complete the electronically administered SIT using a tablet computer. CTCA team members utilize these results as part of their patient assessment and evaluation process. These two complementary processes (patient self-assessment and reflection, and analyzing the data as a starting point for discussion) assure that CTCA care teams readily identify when patients may benefit from referral and/or more directed intervention to help them cope with their symptoms, side effects and quality of life concerns. This data also exists real-time within the electronic health record. Greater than 90% of patients voluntarily participate in the SIT assessments.

The SIT includes 27 items: 13 core symptom questions (box 1) and six questions related to issues that interfere with patients’ everyday functioning (box 2). These 19 questions mirror the MD Anderson Symptom Inventory (MDASI) tool used by many U.S. hospitals. MDASI, which assesses both the severity and impact of patients’ symptoms and quality of life issues, has been psychometrically validated and tested. It is also endorsed by the National Cancer Institute. CTCA has added eight (8) questions to the patient assessment process that our medical and care teams consider clinically relevant (box 3).

Box 1: Core Symptoms Box 2: Interference Issues Box 3: Additional Areas of Focus
Pain, Fatigue, Nausea, Disturbed Sleep, Distress, Shortness of Breath, Memory, Appetite, Drowsy, Dry Mouth, Sadness, Vomiting, Numbness General Activity, Mood, Work, Relationships, Walking, Enjoyment of Life Constipation, Swelling, Mouth Soreness, Bleeding, Sexual Interest, Family Response, Sense of Hope, Quality of Life

The graphs below illustrate CTCA patients’ self-reported symptom burden for nine (9) key areas by type of cancer for patients at their new patient evaluation (baseline) in comparison to their next return visit when scoring a particular symptom or activity area as severe at baseline. For patients with severe baseline scores (7 or greater on a 1 to 10 scale with 1 being “non-existent” and 10 being “as bad as one can imagine/greatly interfered”), a two-point change in score is clinically relevant and significant, with respect to the symptom getting better, remaining constant or getting worse. Data reflects more than 9,983 patients completing a second return assessment from baseline between July 1, 2015 and June 30, 2017, with 2,472 deemed severe.

  1. Basch E, Deal AM, Kris MG, et al: Symptom monitoring with patient-reported outcomes during routine cancer treatment: A randomized controlled trial. J Clin Oncol 10.1200/JCO.2015.63.0830.
  2. Jensen R, Snyder CF: PRO-cision Medicine: Personalizing Patient Care Using Patient-Reported Outcomes. J Clin Oncol 10.1200/JCO.2015.63.0830.
  3. Snyder CF, Herman JM, White SM, et al: When using patient-reported outcomes in clinical practice, the measure matters: A randomized controlled trial. J Oncol Pract 10:e299-e306, 2014.

Quality of life results by cancer type

Breast / Colon / Esophageal / Kidney / Lung / Ovarian / Pancreatic / Prostate / Rectal / Stomach

Back to top

Back to top

Back to top

Back to top

Back to top

Back to top

Back to top

Back to top

Back to top

Back to top

Quality of life results in aggregate and by facility

The following graphs reflect CTCA aggregate as well as facility patient self-reported outcomes (PSRO) data for four key areas related to our ability to treat our patients’ symptoms between July 1, 2015 and June 30, 2017.